Company news

EyePoint, Inc. news in 2023

EyePoint, Inc.'s news releases, calls and decks from 2023, newest first.

View company

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints

December 3, 2023

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

October 31, 2023

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

October 30, 2023

EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023

October 29, 2023

EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023

October 24, 2023

EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team

October 15, 2023

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023

September 10, 2023

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

August 8, 2023

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments

August 1, 2023

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit

July 26, 2023

EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023

July 25, 2023

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

July 9, 2023

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy

June 4, 2023

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 30, 2023

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

May 17, 2023

EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

May 2, 2023

EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

April 25, 2023

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

March 26, 2023

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

March 19, 2023

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

March 1, 2023

EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

February 26, 2023

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

February 22, 2023

EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

January 22, 2023

EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

January 4, 2023

EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

January 3, 2023

Calls in 2023

Decks in 2023